



Transplant Complications Working Party

Chair: Olaf Penack
GvHD subcom: Zinaida Perić
AI subcom: Alberto Mussetti
Nurse: Michelle Kenyon

Secretary: Lars Klingen Gjørde
Survivorship subcom: Hélène Schoemans
CAR-T comps subcom: Charlotte Graham
Early Comps subcom: Ivan Moiseev

Publications in 2025

- Penack O. et al. **GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended.** Leukemia. 2025 Apr 17.
- Guven M. et al. **The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes.** Bone Marrow Transplant. 2025 Apr 17.
- Graham CE. et al. **Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.** Lancet Oncol. 2025 Apr 26.
- Orti G. et al. **Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies.** Bone Marrow Transplant. 2025 Apr 9.
- Gagelmann N. et al. **Daratumumab for PRCA after HCT: study and practical considerations.** Blood Cancer J. 2025 Jun 4.
- Moiseev I. et al. **Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation.** Bone Marrow Transplant. 2025 Aug 19.
- Pulanic D. et al. **Chronic Graft-versus-Host disease trends over 30 years.** Bone Marrow Transplant. 2025 Aug 19.
- Piekarska A. et al. **Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors.** Bone Marrow Transplant. 2025 Sep 11.
- Ramme K. et al. **Late effects after hematopoietic stem cell transplantation in patients with HLH.** J Allergy Clin Immunol. 2025 Sep 26.
- Tomaszewska A. et al. **Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide.** Cancers (Basel). 2025 Dec 18.

Presentations at EBMT 2026

Oral Presentations

- **Charlotte Graham**
Non-relapse mortality following CAR-T – **presidential symposium**

Poster Presentations

- **Guillaume Dachy.** TMA following CAR-T therapy
- **Torsten Schroeder.** CAR-T induced pseudoprogressions (CARTiPP)
- **Guillaume Dachy.** Outcome of CAR-T cell therapy in older patients
- **Matteo Doglio.** Incidence and characteristics of IEC-HLH (w/ GOCART)

Manuscripts in Writing/Finalisation Phase

- **Bilinski J.** Fecal microbiota transplant for GvHD.
- **Dachy G.** TMA after CAR-T cell therapy.
- **Dachy G.** CAR-T cell therapy in elderly (70+) patients.
- **Damm F. & Schetelig J.** CHIP studies.
- **De Wreede L. & Schetelig J.** TROP study.
- **Durakovic N.** Graft rejection in haplo HCT survey.
- **Gjaerde LK.** ATG vs. PTCy in elderly patients.
- **Graham CE.** NRM after CAR-T therapy.
- **Kirgizov K.** Late complications after autoHCT (with ADWP).
- **Mekinian A.** Autoimmune complications of alloHCT.
- **Montoro J.** Lung transplantation after alloHCT.
- **Salooja N.** Pregnancy outcomes among SCT survivors.
- **Schultze-Florey C.** Impact of BMI on CAR-T cell therapy.
- **Schultze-Florey C.** SGLT2 inhibitor survey.
- **Stoelzel F.** Pseudoprogression after CAR-T (CARTiPP).
- **Turki A.** Machine learning and GvHD.

Active Studies

- **Elias S.** CVC and Anticoagulation survey in HCT and CAR-T
- **Moiseev I.** Severity and response in TA-TMA.
- **Nandra T.** Immune effector cell enterocolitis after CAR-T.
- **Novak P.** Secondary HLH post alloHCT.
- **Salooja N. & Horgan C.** Transition from paediatric to adult centres.
- **Perić Z.** Steroid refractory acute GvHD survey.

Upcoming Studies

- **Andreozzi F.** Outcomes in CAR-T patients with comorbidities.
- **Hütter-Kronke L.** Late organ toxicity post CAR-T.
- **Hütter-Kronke L.** AlloSCT in patients over 70 years old.
- **Muratore E.** EASIX score in children (with PDWP).
- **Orti G.** Incidence of GvHD after BCMA targeted CAR-T.
- **Schoemans H.** Long term outcomes of PTCy vs ATG.